Wednesday, 11th November Clinical Oncology Society of Australia Annual Scientific Meeting 2020

8:30AM - 9:00AM
Wednesday, 11th November
Stream A
Chair: Nick Pavlakis
10:30AM - 10:45AM
Wednesday, 11th November
1:00PM - 1:30PM
Wednesday, 11th November
1:30PM - 2:30PM
Wednesday, 11th November
Stream A
Chair: Jeremy Long
Co-chair: Cassandra Dickens

Implementation science is at the core of the Cancer Alliance Queensland safety and quality program. Through a variety of mechanisms; data analysis, customised hospital reporting, dashboards, clinical review and feed back to clinical teams Cancer Alliance Queensland promotes the systematic uptake of key findings into routine practice.  

We take a deep dive into the Queensland Oncology Repository (a data lake) to uncover extensive data resources and insights of practical value to cancer care services, highlighting where the health system is performing well and identifying areas for improvement.

The plenary will comprise 4 oral papers based on population data from the Queensland Oncology Repository which describe the multisided QOOL platform or ‘air bnb’ of cancer data, novel approaches using natural language processing to determine cancer stage and recurrence, assessment of guideline concordant care in the colorectal cancer population and insights into management of adolescent and young adult cancer across Queensland.

The presentations will showcase the commitment of clinicians to creating a “learning cancer care system” which through systematic continuous quality monitoring, data analytics and application of such data informs overall strategies and targeted improvement efforts. The “learning cancer care system” inspires reflection and self-examination of performance in the local setting.  This is an essential tool which aids cancer clinicians in evaluating the delivery of cancer services in Queensland.

The papers will be followed by a panel discussion to explore the following key issues. How do we address implementation gaps across services? Where is a renewed effort needed to improve services? What is acceptable variation in cancer management?

1:30 PM Jeremy Long - Introduction

1:35 PM Shoni Philpot
Transforming digital data into cancer care practice: implementation science in action

1:45 PM Danica Cossio
Natural language processing; a novel approach to determine stage and recurrence for 5 cancer populations

1:55 PM Rick Walker
Utilising big data to inform the management of AYA cancer in Queensland

2:05 PM Euan Walpole
Performing well & room for improvement; spotlight on CRC guideline concordant care

2:15 PM Panel Discussion 

3:45PM - 4:00PM
Wednesday, 11th November
4:00PM - 5:30PM
Wednesday, 11th November
Stream C
Chair: Dan Kent
Co-chair: Meinir Krishnasamy

5:20 PM Panel Discussion

6:00PM - 7:00PM
Wednesday, 11th November
Stream B
Sponsored by:

Time: 6:00pm - 7:00pm AEDT

Description: Real-world evidence (RWE) leveraging observational registries and claims databases has been commonplace for several years and is a concept that has been long-present in healthcare industry. This session will cover the evolving role of RWE in Australia.

Prof John Zalcberg, Head of Cancer Research and NHMRC (MRFF) Practitioner Fellow within the School of Public Health and Preventive Medicine at Monash University and Tony Charlton Chair of Oncology at Alfred Health
Prof Andrew Wilson, Chair of the PBAC
Amanda Ruth, Head of Policy and Public Affairs at Rare Cancers Australia
Simone Leyden, Co-Founder and CEO at NeuroEndocrine Cancer Australia
Michael Coory, Medical Officer, Technology Assessment and Access Division, Department of Health
Dr Margaret Wilson, Dr Sarah Golding, Senior Medical Officer, TGA

Prof Andrew Wilson
Amanda Ruth
Prof John Zalcberg

This symposium is available for virtual attendees. Please register using the button below.

This evening symposium is sponsored by Medicines Australia

7:00PM - 8:30PM
Wednesday, 11th November
Stream A
Chair: Victoria Atkinson
Sponsored by:

Time: 7:00pm - 8:30pm
Date: 11 November 2020

Learning Objectives

The emergence of subsidized immuno-oncology (IO) therapy for the treatment of melanoma in the advanced and adjuvant setting has transformed the way that patients are treated and managed.
During this symposium, our Chair and Speakers will help you understand the latest evidence for KEYTRUDA® (pembrolizumab) and discuss best practice treatment and management considerations for your melanoma patients in both the adjuvant and advanced settings.

By the end of the meeting, you’ll gain:

  • Understanding of the evidence behind KEYTRUDA® in adjuvant & advanced Melanoma
  • Understanding of difference in treatment and management considerations of adjuvant & advanced Melanoma
  • Practical tips in the implementation of KEYTRUDA® in clinical practice of adjuvant & advanced Melanoma

Chair: A/Prof Victoria Atkinson, Medical Oncologist, Princess Alexandra Hospital


A/Prof. Melissa Eastgate, Deputy Director of Medical Oncology, Royal Brisbane and Women’s Hospital

Rebecca Johnson, Clinical Nurse Consultant, Melanoma Institute Australia

This evening symposium is sponsored by MSD Australia

9:00PM - 11:00PM
Wednesday, 11th November
Sponsored by: